Has Josue Castresana received payments from drug or device companies?

Yes. Drug and device makers reported $7,550 in general payments to Josue Castresana across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Josue Castresana did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Josue Castresana come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Josue Castresana

Nephrology · Cayey, PRNPI 1972550259

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,081 of the $7,550 with a category attached, or 67.3%. 20 manufacturers reported payments, led by Johnson & Johnson at 31.6% of the total. Reporting peaked in 2019 at $2,992 and has fallen 63.3% since, to $1,097 in 2025. Among nephrology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,550in general payments, 2019–2025

Across 74 payments — averaging $102.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
Mallinckrodt Hospital Products Inc.$660
AstraZeneca$586
Amgen$492
GSK$473
Calliditas Therapeutics US Inc.$339
plus $3K from 14 others

What the payments were for

Consulting fees$2,04027%
Travel & lodging$2824%
Food & beverage$5,08167%
Education$1472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	6	$2,386
Mallinckrodt Hospital Products Inc.	7	$660
AstraZeneca(2 entities)	8	$586
Amgen(2 entities)	5	$492
GSK	5	$473
Calliditas Therapeutics US Inc.	4	$339
Bayer	6	$285
Fresenius USA Marketing, Inc.	4	$269
Novo Nordisk	3	$263
Cormedix Inc.	1	$261
Otsuka America Pharmaceutical, Inc.	2	$244
ANI Pharmaceuticals, Inc.	9	$226
Vifor Pharma, Inc.	2	$225
Bard Peripheral Vascular, Inc.	2	$214
Travere Therapeutics, Inc.	2	$149
Kyowa Kirin, Inc.	1	$119
Sanofi	2	$118
Mallinckrodt Enterprises LLC	3	$113
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$100
Merck	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,550 in reported general payments places this provider in the 90th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico →

Other nephrology in Cayey

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →